Research Article

Cytotoxic T lymphocyte-Associated Antigen +49G Variant Confers Risk for Anti-CCP- and Rheumatoid Factor-Positive Type of Rheumatoid Arthritis Only in Combination with CT60*G Allele

Bernadett Farago, Peter Kisfali, Lili Magyari, Noemi Polgar, and Bela Melegh

Department of Medical Genetics and Child Development, University of Pecs, Pecs 7624, Hungary

Correspondence should be addressed to Bela Melegh, bela.melegh@aok.pte.hu

Received 4 June 2009; Accepted 2 August 2009

Academic Editor: Rizgar Mageed

Controversial observations have been published on the association of the cytotoxic T lymphocyte associated antigen gene’s variants with rheumatoid arthritis (RA). After genotyping 428 patients and 230 matched controls, the prevalence of the CT60*G allele was more frequent in RF- and/or anti-CCP-seropositive RA patients, compared to the healthy controls (P < .001). Regression analysis revealed that the CT60*G allele is a possible predisposing factor for RA in these subgroups. No accumulation of the +49*G allele was found among patients, and this variant was not found to correlate with RA. Assaying the possible genotype variations, the +49*G-CT60*G allelic combination was accumulated in seropositive RA subtypes, and was associated with the risk of RA (OR = 1.73, P = .001 for the whole RA population). Although the +49*G allele did not mean a predisposition to RA alone, in combination with CT60*G it, also conferred risk, suggesting that the +49A/G variant is associated with the risk of RA only in certain haplotypes.

Copyright © 2010 Bernadett Farago et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

The cytotoxic T lymphocyte associated antigen (CTLA4) is a well-known cosignalling molecule of the B7 receptor immunoglobulin family. CTLA4 is expressed by CD4+, CD8+, T and B lymphocytes, and is located on the surface of the cell. Its expression and its density on the cell surface is affected by the activation of the T lymphocytes. Contrary to CD28, which transmits a stimulatory signal to the T cells by binding to B7-1 or B7-2 receptors on antigen presenting cells, CTLA4 is an inhibitory factor in T-cell activating systems [1].

The CTLA4 gene polymorphisms are reportedly associated with a variety of T cell-mediated autoimmune diseases such as type 1 diabetes mellitus [2, 3], systemic lupus erythematosus, Hashimoto thyroiditis [4], Addison disease [5], Grave’s disease [6–8], multiple sclerosis [9–11], and celiac disease [12, 13]. Previous investigations on the association of CTLA4 with RA [14–22] resulted in controversial outcomes.

Nistico et al. identified a +49A/G transition polymorphism of the leader sequence in exon 1, resulting in a threonine to alanine change at position 17 of the amino acid sequence [2]. In patients carrying the homozygous GG genotype, the hydrophobic alanine is inserted into the highly conservative sequence of the CTLA4 leader peptide. This slight alteration of the leader peptide may affect the intracellular transport of the CTLA4 protein and its availability on the cell surface [23]. As GG homozygotes have fewer functionally active CTLA4 molecules on the cell surface of the T lymphocytes, fewer B7-CTLA4 associations can form, leading to a less efficient CTLA4-mediated T cell inhibition. As a consequence, a significantly increased T cell proliferation can be observed, compared to AA homozygotes [24].

Another polymorphism, the CT60 (A6230G) allele in the 3’-UTR region, encodes either a protective A variant or a predisposing G variant for autoimmune diseases [20]. The G allele is associated with lower mRNA levels of the soluble CTLA4 isoform. Both the +49A/G and the CT60A/G variants have been reported to confer risk for rheumatoid arthritis, however, the results are controversial [14], some findings affirm the role of the SNPs in RA [15, 17, 19, 20], while others could not reveal any association [16, 18, 21, 22]. The
allowing us to monitor the e
the amplicon contained an obligate restriction cleavage site
Inc., Burlington, Ont, Canada). Both methods designed
ommended by the manufacturer (Fermentas International
electrophoresis and visualized by ethidium bromide staining.
A total of 428 well-characterised RA patients (102 males
2. Materials and Methods
A total of 428 well-characterised RA patients (102 males
and chi-square tests to reveal the possible associations
3. Results
In this Hungarian cohort, we chose to evaluate the allele
and genotype distribution of two variants of the CTLL4
Table 1 presents our findings, the allele frequencies of
Table 1. Results of the analysis between the genetic
Table 2. Results of the analysis between the genetic
In RF- and anti-CCP-seropositive subjects the CT60*G allele represented an approximately 1.5-fold risk for the development of RA in our patient population. These results are in agreement with previous findings [19], reporting a slightly lower susceptibility (OR = 1.18, 95%CI: 1.07–1.31, P = .006) in Caucasian patients with anti-CCP-positive RA. Similarly, a Chinese cohort [29] demonstrated a susceptibility of OR = 1.41 (95%CI: 1.10–1.82, P = .005), considering the entire RA population with no regard to anti-CCP seropositivity.

It has been reported that the CT60*G variant is likely associated with the RF-seropositive form of RA [19]. So far no data has been published on samples seropositive, both for RF and anti-CCP. Our examinations revealed a risk of 1.58 (95%CI: 1.23–2.03, P < .001) in the double-seropositive group, which is similar to that observed in the subgroups characterized by seropositivity for either RF or anti-CCP (OR = 1.52, 95%CI: 1.20–1.93, P = .001; and OR = 1.58, 95%CI: 1.24–2.02, P < .001, resp.).

Based on the relatively high ratio of patients with the homozygous CT60*G genotype, we hypothesize that the CT*60G is a susceptibility factor for RA in the Hungarian population. Furthermore, the CT60*G homozygous state represents an approximately 2-fold risk for RA in the seropositive subsets of samples, compared to the risk of carrying the G allele in a heterozygous form. This may

**Table 1:** The distribution and frequencies of the CTLA4 CT60 and +49A/G genotypes and alleles, and the +49*G-CT60*G haplotype stratified by RF- and anti-CCP-seropositivity in patients versus controls.

| | RA patients | Control |
|---|---|---|
| | RF | anti-CCP | RF + anti-CCP | |
| Total (n = 428) | (n = 324) | (n = 104) | (n = 310) | (n = 118) | (n = 286) | (n = 80) | (n = 230) |
| CT60 | | | | | | | |
| AA (%) | 84 (19.6)* | 62 (19.1)* | 22 (21.2) | 59 (19.0)* | 25 (21.2) | 54 (18.9)* | 17 (21.3) | 64 (24.0) |
| GA (%) | 199 (46.5) | 143 (44.1) | 56 (53.8) | 131 (42.3) | 68 (57.6) | 122 (42.7) | 47 (58.8) | 109 (48.8) |
| GA+GG (%) | 344 (80.4) | 262 (80.9) | 82 (78.8) | 251 (81.0) | 93 (78.8) | 232 (81.1) | 63 (78.8) | 166 (78.4) |
| GG (%) | 145 (33.9)* | 119 (36.7)* | 26 (25.0) | 120 (38.7)* | 25 (21.2) | 110 (38.5)* | 16 (20.0) | 57 (27.1) |
| G (%) | 489 (57.1)* | 381 (58.8)* | 108 (51.9) | 371 (59.8)* | 118 (50.0) | 342 (59.8)* | 79 (49.4) | 223 (48.5) |

+49A/G

| | |
|---|---|
| AA (%) | 160 (37.4) |
| GA (%) | 201 (47.0) |
| GA+GG (%) | 268 (62.6) |
| GG (%) | 67 (15.7) |
| G (%) | 335 (39.1) |

+49*G-CT60*G 182 (21.3)* 147 (22.7)* 35 (16.8) 147 (23.7)* 35 (14.8) 134 (23.4)* 22 (13.8) 62 (13.5)*

*P < .05 in the prevalence of the AA and GG genotypes, the G allele, or the +49*G-CT60*G haplotype versus controls.

**Table 2:** The results of the binary logistic regression analyses considering the CTLA4 CT60 genotypes, the CT60*G allele, and the +49*G-CT60*G haplotype in RA patients stratified by RF- and anti-CCP-seropositivity versus controls.

| RA Patients | |
|---|---|
| RF | anti-CCP | RF + anti-CCP |
| Total (n = 80) | (n = 324) | (n = 104) | (n = 310) | (n = 118) | (n = 286) | (n = 80) |
| CT60*GG | | | |
| OR (95%CI) | 1.56 (1.09–2.23) | 1.76 (1.21–2.56) | 1.01 (0.59–1.73) | 1.92 (1.32–2.79) | 0.82 (0.48–1.39) | 1.90 (1.29–2.78) | 0.76 (0.41–1.42) |
| P | .016 | .003 | .966 | .001 | .455 | .001 | .386 |
| CT60*G | | | | | | | |
| OR (95%CI) | 1.42 (1.13–1.78) | 1.52 (1.20–1.93) | 1.15 (0.83–1.60) | 1.58 (1.24–2.02) | 1.06 (0.78–1.46) | 1.58 (1.23–2.03) | 1.04 (0.72–1.49) |
| P | .003 | .001 | .410 | < .001 | .145 | < .001 | .845 |
| +49*G - CT60*G | | | | | | | |
| OR (95%CI) | 1.73 (1.27–2.37) | 1.88 (1.36–2.61) | 1.30 (0.83–2.04) | 2.00 (1.44–2.76) | 1.12 (0.71–1.75) | 1.96 (1.41–2.73) | 1.02 (0.61–1.73) |
| P | .001 | < .001 | .256 | < .001 | .626 | < .001 | .931 |
suggest a gene dose dependency in influencing disease susceptibility although the presence of two copies of the CT60*G variant does not mean an actual double risk, compared to a single copy of the variant.

Contrary to our findings and previous reports [19], some other studies on a Caucasian patient population failed to demonstrate any associations between the CT60*G variant and rheumatoid arthritis [22]. A likely explanation for this controversy is that cohorts including relatively small number of samples might fail to detect statistically significant differences, since the allele frequencies of the CT60 A and G variants are similar to each other in the general population. However, marginally significant differences regarding the susceptibility alleles may be detected in the patient group. Furthermore, the odds ratios found are relatively low (approximately OR = 1.5), therefore, it would not be surprising if studies with smaller sample size could not reveal any significant correlation between the possible risk alleles and the disease. Another explanation is that the above controversy might be due to heterogeneity across study populations, where a susceptibility allele identified in one population has no disease-association in another population.

Considering the +49A/G polymorphism, we could not detect any significant differences regarding the genotype and allele distributions of the RA and control samples (Table 1). Previous works [15–22] documented controversial outcomes on the possible association between this variant and RA. It is possible, that the +49A/G polymorphism does not increase disease susceptibility alone, but together with other predisposing factors, it increases the risk for developing RA, as some studies [17, 30, 31] demonstrated an association in HLA-DRB1*04 patients, while others [16, 22] found no association irrespective of the HLA-shared epitope status. A study on Chinese patients [29] suggested that CT60 is a possible independent causal variant in RA, and that the effect of the +49G variant is dependent on the CT60*G allele, since when the +49G allele is combined with the CT60*G in a haplotype, their effect is increased. We were not able to replicate these findings in our study (data not shown), although it is possible that the correlations found in Asian populations do not stand for Caucasians.

The exact molecular background of how the predisposing CT60*G variant affects CTLA4 function and thus T-cell activation is not fully understood. A recent report [20] indicated that the CT60 variant influences the splicing and production of soluble CTLA4, and that the CT60*G allele is associated with lower mRNA levels of the soluble CTLA4 isoform compared to the protective CT60*A variant. A smaller amount of functionally intact CTLA4 molecules will hinder the T-cell-attenuation, as the interaction between B7 receptor and CTLA4 is less efficient. A defect of this attenuating system may, therefore, be an important risk factor in the development of RA. Contrary to this, a recent study [32] could not support this hypothesis.

5. Conclusions

Although the molecular mechanisms through which the CT60 variant of CTLA4 exerts its effect in the development of autoimmune diseases are yet to be clarified, it should be emphasized that the CTLA4 CT60*G variant represents an 1.5-fold risk for the development of RA in the Hungarian sets of RF- and/or anti-CCP-seropositive rheumatoid arthritis patients. Since a relatively small number of studies have been conducted and controversial findings have been reported on the role of the +49A/G and the CT60 genetic variants in the development of RA, further investigations are required.

Acknowledgments

This work was supported by the grants of Hungarian Scientific Research Foundation OTKA T 49589 and T 73430, by the grant of the Hungarian Ministry of Health: ETT 497/2006, as well as by the grant of Peter Pazmany Program RET-008/2005. We are grateful to Edit Papp, Judit Okai, Marta Hartung, and Eva Auguszt for their excellent technical assistance. The authors warrant that none of the authors have any conflict of interest.

References

[1] G. Magistrelli, P. Jeannin, G. Elson, et al., “Identification of three alternatively spliced variants of human CD28 mRNA,” Biochemical and Biophysical Research Communications, vol. 259, no. 1, pp. 34–37, 1999.
[2] L. Nistico, R. Buzzetti, L. E. Pritchard, et al., “The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian diabetes registry,” Human Molecular Genetics, vol. 5, no. 7, pp. 1075–1080, 1996.
[3] P. A. Zalloua, A. Abchee, H. Shbaklo, et al., “Patients with early onset of type 1 diabetes have significantly higher GG genotype at position 49 of the CTLA4 gene,” Human Immunology, vol. 65, no. 7, pp. 719–724, 2004.
[4] H. Donner, J. Braun, C. Seidl, et al., “Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in hashimoto’s thyroiditis and addison’s disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 12, pp. 4130–4132, 1997.
[5] A. Blomhoff, B. A. Lie, and A. G. Myhre, “Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to addison’s disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 7, pp. 3474–3476, 2004.
[6] J. M. Heward, A. Allahabadia, M. Armitage, et al., “The development of Graves’ disease and the CTLA4 gene on chromosome 2q33,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 7, pp. 2398–2401, 1994.
[7] Y. Ban, E. S. Concepcion, R. Villanueva, et al., “Analysis of immune regulatory genes in familial and sporadic Graves’ disease,” Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 9, pp. 4562–4568, 2004.
[8] K. Furugaki, S. Shirasawa, N. Ishikawa, et al., “Association of the T-cell regulatory gene CTLA4 with Graves’ disease and autoimmune thyroid disease in the japanese,” Journal of Molecular Genetics, vol. 65, no. 7, pp. 719–724, 2004.
[9] V. Suppiah, I. Alloza, S. Hegarty, et al., “The CTLA4 +49 A/G - CT60* G haplotype is associated with susceptibility to multiple sclerosis in flanders,” Journal of Neuroimmunology, vol. 164, no. 1-2, pp. 148–153, 2005.
Autoimmune Diseases

[10] G. Malferrari, A. Stella, E. Monferini, et al., “Ctla4 and multiple sclerosis in the italian population,” *Experimental and Molecular Pathology*, vol. 78, no. 1, pp. 55–57, 2005.

[11] A. Ligers, N. Teleshova, T. Masterman, et al., “CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms,” *Genes and Immunity*, vol. 2, no. 3, pp. 145–152, 2001.

[12] A. L. King, S. J. Moodie, J. S. Fraser, et al., “Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region,” *European Journal of Immunogenetics*, vol. 30, no. 6, pp. 427–432, 2003.

[13] M. J. van Belzen, C. J. Mulder, A. Zhernakova, et al., “CTLA4 + 49 A/G and CT60 polymorphisms in Dutch coeliac disease patients,” *European Journal of Human Genetics*, vol. 12, no. 9, pp. 782–785, 2004.

[14] V. Suppiah, C. O’Doherty, S. Heggarty, et al., “The CTLA4 + 49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland,” *Experimental and Molecular Pathology*, vol. 80, no. 2, pp. 141–146, 2006.

[15] B. Vaidya, S. H. Pearce, S. Charlton, et al., “An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies,” *Rheumatology*, vol. 41, no. 2, pp. 180–183, 2002.

[16] A. Barton, A. Myerscough, S. John, et al., “A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis,” *Rheumatology*, vol. 39, no. 1, pp. 63–66, 2000.

[17] C. Seidl, H. Donner, B. Fischer, et al., “CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis,” *Tissue Antigens*, vol. 51, no. 1, pp. 62–66, 1998.

[18] A. Zhernakova, P. Eerlich, P. Barrera, et al., “CTLA4 is differentially associated with autoimmune diseases in the Dutch population,” *Human genetics*, vol. 118, no. 1, pp. 58–66, 2005.

[19] R. M. Plenge, L. Padyukov, E. F. Remmers, et al., “Replication of putative candidate-gene associations with rheumatoid arthritis in > 4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PAD14,” *American Journal of Human Genetics*, vol. 77, no. 6, pp. 1044–1060, 2005.

[20] H. Ueda, J. M. Howson, L. Esposito, et al., “Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease,” *Nature*, vol. 423, no. 6939, pp. 506–511, 2003.

[21] C.-S. Lee, Y.-J. Lee, H.-F. Liu, et al., “Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese,” *Clinical Rheumatology*, vol. 22, no. 3, pp. 221–224, 2003.

[22] G. Orozco, B. Torres, A. Nunez-Roldan, et al., “Cytotoxic T-lymphocyte antigen-4 CT60 polymorphism in rheumatoid arthritis,” *Tissue Antigens*, vol. 64, no. 6, pp. 667–670, 2004.

[23] S. M. Anjos, W. Shao, L. Marchand, et al., “Allelic effects on gene regulation at the autoimmune-predisposing CTLA4 locus: a re-evaluation of the 3’ +6230G > A polymorphism,” *Genes and Immunity*, vol. 6, no. 4, pp. 305–311, 2005.

[24] M. Maurer, S. Loserth, A. Kolb-Maurer, et al., “A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 + 49) alters T-cell activation,” *Immunogenetics*, vol. 54, no. 1, pp. 1–8, 2002.

[25] F. C. Arnett, S. M. Edworthy, D. A. Bloch, et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” *Arthritis and Rheumatism*, vol. 31, no. 3, pp. 315–324, 1988.

[26] B. Farago, G. C. Talian, A. Maasz, et al., “Prevalence of functional haplotypes of the peptidylarginine deiminase citrullinating enzyme gene in patients with rheumatoid arthritis: no influence of the presence of anti-citrullinated peptide antibodies,” *Clinical and Experimental Rheumatology*, vol. 25, no. 4, pp. 523–528, 2007.

[27] B. Farago, L. Magyari, E. Safrany, et al., “Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis,” *Annals of the Rheumatic Diseases*, vol. 67, no. 2, pp. 248–250, 2008.

[28] K. Komlosi, G. C. Talian, B. Farago, et al., “No influence of SLC22A4 C6607T and RUNX1 G24658C genotypic variants on the circulating carnitine ester profile in patients with rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 26, no. 1, pp. 61–66, 2008.

[29] C. Lei, Z. Dongqing, S. Yeqing, et al., “Association of the CTLA-4 gene with rheumatoid arthritis in chinese han population,” *European Journal of Human Genetics*, vol. 13, no. 7, pp. 823–828, 2005.

[30] M. Matsushita, N. Tsuchiya, M. Shiota, et al., “Lack of a strong association of CTLA-4 exon 1 polymorphism with the susceptibility to rheumatoid arthritis and systemic lupus erythematosus in japanese: an association study using a novel variation screening method,” *Tissue Antigens*, vol. 54, no. 6, pp. 578–584, 1999.

[31] T. Yanagawa, K. Gomi, E. I. Nakao, et al., “CTLA-4 gene polymorphism in japanese patients with rheumatoid arthritis,” *Journal of Rheumatology*, vol. 27, no. 12, pp. 2740–2742, 2000.

[32] S. Purohit, R. Podolsky, C. Collins, et al., “Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes,” *Journal of Autoimmune Diseases*, vol. 2, no. 8, 2005.